Publication | Closed Access
New Method for Fast and Accurate Binding‐site Identification and Analysis
886
Citations
4
References
2007
Year
Drug TargetHit IdentificationStructural BioinformaticsMolecular BiologyLead IdentificationKnown Binding SiteMedicinal ChemistryMolecular RecognitionBiochemistryStructure-based Drug DesignBiomedical AnalysisPharmacologyBioinformaticsStructural BiologyMolecular DockingAccurate Binding‐site IdentificationLigand-based Drug DesignNatural SciencesRational Drug DesignMedicinePotential Binding SitesDrug Discovery
Structure‑based drug design seeks to exploit protein‑ligand or protein‑protein binding sites, yet the site is not always known, alternative sites may exist, and understanding binding‑site complementarity is vital for lead optimization. SiteMap was developed to identify potential binding sites and predict their druggability in lead‑discovery applications. SiteMap also characterizes binding sites and critically assesses prospective ligands in lead‑optimization applications. In large‑scale validation, SiteMap correctly identifies known binding sites in >96 % of cases, distinguishes binding from non‑binding sites, and provides quantitative and graphical data to guide ligand modification, complementing docking and computational lead optimization.
Structure-based drug design seeks to exploit the structure of protein-ligand or protein-protein binding sites, but the site is not always known at the outset. Even when the site is known, the researcher may wish to identify alternative prospective binding sites that may result in different biological effects or new class of compounds. It is also vital in lead optimization to clearly understand the degree to which known binders or docking hits satisfy or violate complementarity to the receptor. SiteMap is a new technique for identifying potential binding sites and for predicting their druggability in lead-discovery applications and for characterizing binding sites and critically assessing prospective ligands in lead-optimization applications. In large-scale validation tests, SiteMap correctly identifies the known binding site in > 96% of the cases, with best results (> 98%) coming for sites that bind ligands tightly. It also accurately distinguishes between sites that bind ligands and sites that don't. In binding-site analysis, SiteMap provides a wealth of quantitative and graphical information that can help guide efforts to modify ligand structure to enhance potency or improve physical properties. These attributes allow SiteMap to nicely complement techniques such as docking and computational lead optimization in structure-base drug design.
| Year | Citations | |
|---|---|---|
Page 1
Page 1